戻る Agenda
[S07] Ideal Conduct and Future Perspectives for Publication by Pharmaceutical Companies
Session Chair(s)
Yuko Kojima, RPh
Sr. Executive Director
Eli Lilly Japan K.K., Japan
Company-sponsored publications are one of the most critical sources of medical information to help HCPs decide treatment for a patient. So, it is very important to understand what pharmaceutical companies should do to ensure ethical and effective publications to have the evidence appropriately communicated and to avoid any misconduct. In this session, we will readdress the publication basics such as Good Publication Practice 3 (GPP3) and ICMJE recommendations with international publication experts. We will also discuss current practices and challenges which a Japanese pharmaceutical company faces in a real setting. On top of these, we will touch upon future outlook such as how to involve patients in publications.
Speaker(s)
What Journal Editors Expect from the Pharmaceutical Industry?
Ana Marušic, MD, PhD
University of Split School of Medicine, Croatia (Hrvatska)
Professor and Chair, Department of Research in Biomedicine and Health
Current and Future Publication Practice by Pharmaceutical Company
Audrey Krolicki, PharmD
Astellas Pharma, United States
Executive Director, Head of Medical Information
Current Status and Issues of Publication Management from Inhouse Perspective
Ken-ichi Setsukinai, PhD
SHIONOGI & CO., LTD., Japan
Medical Affairs Division, Medical communication group manager